The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib
Clinical trial NCT04179890 · COMPLETED
Trial details
- NCT number
- NCT04179890
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2019-12-17
- Primary completion
- 2021-07-22
- Enrollment
- 462
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.